Navigation Links
Seasonal Influenza Activity Increasing Across Europe - H3N2 Dominant Strain
Date:1/19/2009

inues to support the activities of the Neuraminidase Inhibitor Susceptibility Network (NISN).

Sensitivity of H5N1 (bird flu) to Tamiflu

Recently published data confirms that the H5N1 avian influenza (bird flu) strain remains sensitive to Tamiflu. Greater than ninety nine percent of H5N1 samples studied did not exhibit mutations that confer oseltamivir resistance.(3)

According to Benjamin Schwartz, MD, CDC National Vaccine Program Office, "the mutations that have made the H1N1 virus resistant are unlikely to occur in a pandemic virus, so therefore we have not changed our recommendations for planning and stockpiling".(4) Tamiflu remains the World Health Organization's "primary recommended antiviral agent of choice for the treatment of A(H5N1) virus infections".(5)

References

(1) EISS - Weekly Electronic Bulletin Week 2 :05/01/2009-11/01/2009 16 January 2009, Issue No 287

(2) The Centres for Disease Control and Prevention (CDC). Interim Antiviral Guidance for 2008-09 http://www2a.cdc.gov/HAN/ArchiveSys/ViewMsgV.asp?AlertNum=00279 Accessed 6 January 2009

(3) Hill AW et al. Evolution of drug resistance in multiple distinct lineages of H5N1 avian influenza. Infections, Genetics and Evolution. 2008

(4) 'Cost, resistance aired in HHS webcast on antivirals'. CIDRAP News. December 17 2008 http://www.cidrap.umn.edu/cidrap/content/influenza/panflu/news/dec1708webinar. html Accessed 16 January 2009

(5) Clinical management of human infection with avian influenza A(H5N1) virus. World Health Organization. 15 August 2007 http://www.who.int/csr/
'/>"/>

SOURCE Roche
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Novavax to Present Seasonal Influenza Data Results in an Investor Conference Call on December 11, 2008
2. Novavax Completes Enrollment of Its Seasonal Influenza VLP Vaccine Phase IIa Clinical Trial
3. Novavax Commences Clinical Testing of its Seasonal Influenza VLP Vaccine Candidate
4. Sinovac Launches Seasonal Influenza Vaccine Anflu(R) for 2008-2009 Flu Season
5. Rising H9N2 Influenza Replikin Count Has Doubled That of H5N1
6. DaVita Launches Flu Fighter Program in Support of National Influenza Week
7. Lentigen Corporation and PATH Announce Partnership on Innovative Vaccine for Pandemic Influenza
8. A New Way to Predict Outbreaks: Replikin Peptide Concentration in H5N1 Influenza Virus Genome as a Marker for Lethal Outbreaks
9. BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza
10. Peramivir Phase 2 Data for the Treatment of Outpatient Influenza to be Presented at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
11. MedImmune Licenses Reverse Genetics Technology to Hungarys Omninvest for Use in Influenza Vaccine Development and Production
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015 AACC welcomed ... the 2015 AACC Annual Meeting & Clinical Lab ... July 26–30. The meeting showcased revolutionary advancements in ... ability of healthcare providers to diagnose patients quickly ... medical treatment. As of Wednesday, ...
(Date:7/30/2015)... Dallas, Texas (PRWEB) , ... July 30, 2015 , ... ... professional and in-depth study on the current state of the global Propanol market with ... are Sinopec, CNPC, BASF, Eastman, Dow, Carboclor, Mitsui Chemicals, Oxea, ISU Chemical, Sanofi, Royal ...
(Date:7/30/2015)... CITY, Kan. , July 30, 2015 /PRNewswire/ ... ), a pet therapeutics company focused on the ... for companion animals, today announced that its strategic ... from a dose confirmation study of AT-016, an ... Aratana for the treatment of osteoarthritis pain in ...
(Date:7/30/2015)... Denmark , July 30, 2015 ... biotechnology company that applies its innovative TransCon technology ... positive top-line results from a six-month Phase 2 ... once-weekly TransCon Growth Hormone in 53 treatment-naïve, pre-pubertal ... "We are extremely pleased with the top-line ...
Breaking Biology Technology:Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
... Surgery Portfolio , , ... Johnson & Johnson (NYSE: JNJ ) ... a fully integrated biopharmaceutical company that develops and markets ... whereby Omrix will be acquired for approximately $438 million ...
... NOVATO, Calif., Nov. 21 BioMarin Pharmaceutical,Inc. (Nasdaq: BMRN ... retire from the company on February 27, 2009. Dr. Kakkis ... to be able to,devote more of his time to personal endeavors ... consultant for the company for the foreseeable,future. , ...
... the association for,Michigan,s biosciences industry, welcomed nearly 500 ... Expo on Tuesday and Wednesday of,this week at ... The MichBio Expo is,the premier annual gathering of ... attracted 56 exhibitors. The 2009 Expo is,planned for ...
Cached Biology Technology:Johnson & Johnson Announces Definitive Agreement to Acquire Omrix 2Johnson & Johnson Announces Definitive Agreement to Acquire Omrix 3Johnson & Johnson Announces Definitive Agreement to Acquire Omrix 4Johnson & Johnson Announces Definitive Agreement to Acquire Omrix 5BioMarin Announces the Planned Retirement of Dr. Emil Kakkis, Chief Medical Officer 2BioMarin Announces the Planned Retirement of Dr. Emil Kakkis, Chief Medical Officer 3BioMarin Announces the Planned Retirement of Dr. Emil Kakkis, Chief Medical Officer 4MichBio Expo Draws Nearly 500 Professionals; Career Day Raises Profile 2MichBio Expo Draws Nearly 500 Professionals; Career Day Raises Profile 3
(Date:7/27/2015)... 27, 2015  Synaptics Inc. (NASDAQ: SYNA ... today announced that Huawei has selected the Synaptics ... its stylish smartwatch. Huawei chose the state-of-the-art ClearPad ... power and highly responsive human interface qualities such ... also required a classic round watch face and ...
(Date:7/21/2015)... July 21, 2015 Today, ZTE announced its ... as well as expected revenues in 2015 that relate to sales ... revenue guidance of approximately 2,200 MSEK for 2015. Jörgen ... leading smartphone manufacturer in China and we ... 02 5 for Axon , ...
(Date:7/13/2015)... , July 13, 2015 Synaptics Inc. ... human interface solutions, today announced sampling of ClearPad ... display driver integration (TDDI) product targeting smartphones and ... to combine Synaptics , best-in-class touch controller ... driver technology developed in the company,s Japan Design ...
Breaking Biology News(10 mins):Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3
... University has used a new method of combining multiple ... high numbers of methamphetamine-related problems per capita, giving officials ... The study, presented today at a toxicology conference in ... counties with the most meth-linked incidents per capita, such ...
... 2008) More than 30 years ago, Alfred Knudson ... by showing that a person must lose both their ... cancer-inhibiting genes, called tumor-suppressor genes, in order to develop ... around the globe in their quest for tumor suppressor ...
... Harvard Medical School investigator Gary Ruvkun, PhD, is one of ... Research. Presented by the Albert and Mary Lasker Foundation, ... the Nobel Prize, and many Lasker recipients have gone on ... in New York on Friday, Sept. 26. Ruvkun ...
Cached Biology News:New method identifies meth hot spots 2New method identifies meth hot spots 3'1-hit' event provides new opportunity for colon cancer prevention, say Fox Chase researchers 2MGH researcher Gary Ruvkun named a co-recipient of the Lasker Award 2MGH researcher Gary Ruvkun named a co-recipient of the Lasker Award 3
Determin interaction of your protein with Echelons lipids...
Anti-Human Complement Component C4c, IgY fraction (Polyclonal) (chicken IgY)...
... skirted micro test tubes are used to ... these tubes have uniform walls for uniform ... separate O-ring screw caps. The O-rings are ... an operating range from -55 to 150 ...
... Affi-Prep protein A media yield highly ... prior to analysis of other immunoglobulin ... antigen purification. Protein A binds to ... IgG from mammalian species. This ready-to-use, ...
Biology Products: